NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome

Blood

Volumn 109, Issue 10, 2007, Pages 4306-4312

  Gazit, Roi ^a   Aker, Memet ^b   Elboim, Moran ^a   Achdout, Hagit ^a   Katz, Gil ^a   Wolf, Dana G ^b   Katzav, Shulamit ^a   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD16 ANTIGEN; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RAB27A PROTEIN; VAV PROTEIN;

ARTICLE; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GRISCELLI SYNDROME; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONSENSE MUTATION; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 34248370215     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-047159     Document Type: Article

References (56)

1. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004;25:670-676.
2. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23:255-259.
3. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. NK cell regulation of T cell-mediated responses. Mol Immunol. 2005;42:451-454.
4. Hanna J, Gonen-Gross T, Fitchett J, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest. 2004;114:1612-1623.
5. Biassoni R, Cantoni C, Pende D, et al. Human natural killer cell receptors and co-receptors. Immunol Rev. 2001;181:203-214.
6. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Surface receptors that regulate the NK cell function: beyond the NK cell scope. Curr Top Microbiol Immunol. 2002;266:11-22.
7. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
8. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am J Med. 1978;65:691-702.
9. Pastural E, Barrat FJ, Dufourcq-Lagelouse R, et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet. 1997;16:289-292.
10. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25:173-176.
11. Menasche G, Ho CH, Sanal O, et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest. 2003;112:450-456.
12. Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev. 2005;203:165-179.
13. Augugliaro R, Parolini S, Castriconi R, et al. Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol. 2003;33:1235-1241.
14. Kumar M, Sackey K, Schmalstieg F, Trizna Z, Elghetany MT, Alter BP. Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis. J Pediatr Hematol Oncol. 2001;23:464-468.
15. Bizario JC, Feldmann J, Castro FA, et al. Griscelli syndrome: characterization of a new mutation and rescue of T-cytotoxic activity by retroviral transfer of RAB27A gene. J Clin Immunol. 2004;24:397-410.
16. Klein C, Philippe N, Le Deist F, et al. Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr. 1994;125:886-895.
17. Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:295-300.
18. Plebani A, Ciravegna B, Ponte M, Mingari MC, Moretta L. Interleukin-2 mediated restoration of natural killer cell function in a patient with Griscelli syndrome. Eur J Pediatr. 2000;159:713-714.
19. Kurugol Z, Ozkinay F, Vardar F, et al. Griscelli syndrome: report of a case and review of the literature. Pediatr Int. 2001;43:298-301.
20. Schuster F, Stachel DK, Schmid I, et al. Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT. Bone Marrow Transplant. 2001;28:409-412.
21. Stinchcombe JC, Barral DC, Mules EH, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 2001;152:825-834.
22. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306:1517-1519.
23. Chiesa S, Tomasello E, Vivier E, Vely F. Coordination of activating and inhibitory signals in natural killer cells. Mol Immunol. 2005;42:477-484.
24. Arnon TI, Markel G, Mandelboim O. Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol. 2006;16:348-358.
25. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol. 2001;31:2680-2689.
26. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409:1055-1060.
27. Arnon TI, Achdout H, Levi O, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005;6:515-523.
28. Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest. 2002;110:943-953.
29. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991;11:1912-1920.
30. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis: report of 122 children from the International Registry: FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
31. Menasche G, Fischer A, de Saint Basile G. Griscelli syndrome types 1 and 2 [letter]. Am J Hum Genet. 2002;71:1237-1238; author reply 1238.
32. Baumeister FA, Stachel D, Schuster F, et al. Accelerated phase in partial albinism with immunodeficiency (Griscelli syndrome): genetics and stem cell transplantation in a 2-month-old girl. Eur J Pediatr. 2000;159:74-78.
33. Bahadoran P, Busca R, Chiaverini C, et al. Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome. J Biol Chem. 2003;278:11386-11392.
34. Menasche G, Feldmann J, Houdusse A, et al. Biochemical and functional characterization of Rab27a mutations occurring in Griscelli syndrome patients. Blood. 2003;101:2736-2742.
35. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A. 1999;96:5640-5644.
36. Sulica A, Morel P, Metes D, Herberman RB. Igbinding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol. 2001;20:371-414.
37. Sun PD. Structure and function of natural-killer-cell receptors. Immunol Res. 2003;27:539-548.
38. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290.
39. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190:1505-1516.
40. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2005;8:8.
41. Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Signal. 2004;16:1-11.
42. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol. 2004;22:405-429.
43. Matis LA. The molecular basis of T-cell specificity. Annu Rev Immunol. 1990;8:65-82.
44. Colucci F, Schweighoffer E, Tomasello E, et al. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol. 2002;3:288-294.
45. Colucci F, Rosmaraki E, Bregenholt S, et al. Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. J Exp Med. 2001;193:1413-1424.
46. Lowin-Kropf B, Kunz B, Beermann F, Held W. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1. J Immunol. 2000;165:1314-1321.
47. Fujikawa K, Miletic AV, Alt FW, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med. 2003;198:1595-1608.
48. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996;103:408-413.
49. Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998;187:117-122.
50. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002;109:1501-1509.
51. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005;202:1001-1012.
52. Lopez-Botet M, Angulo A, Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens. 2004;63:195-203.
53. Graham DB, Cella M, Giurisato E, et al. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol. 2006;177:2349-2355.
54. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol. 2006;7:524-532.
55. Saborit-Villarroya I, Del Valle JM, Romero X, et al. The adaptor protein 3BP2 binds human CD244 and links this receptor to Vav signaling, ERK activation, and NK cell killing. J Immunol. 2005;175:4226-4235.
56. Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM. Centrosome polarization delivers secretory granules to the immunological synapse. Nature. 2006;443:462-465.